Please provide your email address to receive an email when new articles are posted on . Wakefulness-promoting agents appear to reduce excessive daytime sleepiness in patients with obstructive sleep ...

One drug stood out for reducing excessive daytime sleepiness (EDS) in patients with obstructive sleep apnea (OSA) in a meta-analysis, researchers reported. Compared with placebo, users of solriamfetol ...

WESTCHESTER, Ill. – A study published in the October 15 issue of the Journal of Clinical Sleep Medicine (JCSM) finds that modafinil is well-tolerated in the treatment of excessive sleepiness ...

A systematic review and analysis of 14 trials found that solriamfetol, armodafinil–modafinil, and pitolisant reduce excessive daytime sleepiness (ESA) for patients with obstructive sleep apnea (OSA) ...

If you've spent time researching wakefulness-promoting medications, you've almost certainly come across two names: mod ...

Many patients experience excessive daytime sleepiness (EDS) despite treatment for obstructive sleep apnea (OSA) and may benefit from wake-promoting drugs. Patients with excessive daytime sleepiness ...

Solriamfetol (Sunosi), a norepinephrine–dopamine reuptake inhibitor, is probably more effective than other wakefulness-promoting medications in patients with obstructive sleep apnea (OSA) who have ...